1352925-63-3

Usage

Uses

Used in Pharmaceutical Synthesis:
Ethyl 4,6-dihydroxypyridazine-3-carboxylate is used as a building block for the synthesis of various pharmaceuticals. Its dihydroxypyridazine and carboxylate functional groups facilitate chemical reactions that can lead to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Synthesis:
In the agrochemical industry, ethyl 4,6-dihydroxypyridazine-3-carboxylate is utilized as an intermediate in the production of agrochemicals. Its chemical properties allow for the creation of compounds that can be used in crop protection and other agricultural applications.
Used in Medicinal Chemistry Research:
Due to its structural features, ethyl 4,6-dihydroxypyridazine-3-carboxylate is used as a subject of research in medicinal chemistry. Scientists explore its potential pharmacological properties and how it can be modified or combined with other compounds to develop new medications or enhance existing ones.
While the provided materials do not specify particular applications in different industries beyond the general categories of pharmaceuticals and agrochemicals, the compound's versatility suggests it may find use in a variety of chemical and biological research areas, pending further exploration and development.

Upstream product

• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 64-19-7 acetic acid 

Downstream Products

• 679406-03-2 4,6-Dichloro-pyridazine-3-carboxylic acid ethyl ester 
• 1609392-27-9 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d₃)pyridazine-3-carboxamide 
• 1442437-21-9 4,6-dihydroxypyridazine-3-carboxylic acid 

Relevant academic research and scientific papers

GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF

The present invention provides pyrazoles, isoxazoles, isothiazoles, thiadiazoles, and pyridazines according to Formula I as described herein, and pharmaceutically acceptable salts thereof. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.

SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS

The present invention relates to a compound of the general formula (1). wherein the pyranose ring is a-D-galactopyranose, A is selected from The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns compounds for use in a method of treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

PYRIDAZINE COMPOUNDS AS JAK INHIBITORS

In one aspect, the invention provides a compound according to formula I, as well as tautomers, pharmaceutically acceptable salts, and hydrates thereof. Pharmaceutical compositions, methods of inhibiting Janus kinases (JAKs), and methods for treating a con

AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.

Imidazol-1-ylmethyl pyridazine derivatives

The invention provides imidazol-1-ylmethyl pyridazine derivatives of the formula: 1 that bind to GABAA receptors. In the above formula, R1, R2 R3, R4, R5, R6 and Ar are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals, and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).